De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

June 28, 2019

Primary Completion Date

June 25, 2024

Study Completion Date

December 31, 2025

Conditions
Oropharyngeal Cancer
Interventions
RADIATION

Radiation

"35 fractions, 5/wk, 7 wks 70Gy/56Gy, or~35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or~35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy"

DRUG

Cisplatin

100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks

Trial Locations (14)

V2M 7E9

BCCA - Centre for the North, Prince George

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

A1B 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 2V7

Kingston Health Sciences Centre, Kingston

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

University Health Network, Toronto

H3T 1E2

The Jewish General Hospital, Montreal

H4A 3J1

The Research Institute of the McGill University, Montreal

G1R 2J6

Hotel-Dieu de Quebec, Québec

J1H 5N4

CIUSSS de l'Estrie - Centre hospitalier, Sherbrooke

S4T 7T1

Allan Blair Cancer Centre, Regina

All Listed Sponsors
lead

Canadian Cancer Trials Group

NETWORK